TFF Pharmaceuticals — Investor Presentation (February 2023)
32 slides from TFF Pharmaceuticals's investor presentation, Feb 16, 2023
Slide 1: Corporate Investor Presentation February 2023
1 NASDAQ: TFFP Corporate Investor Presentation February 2023 BETTER DELIVERY, BETTER THERAPY | Powerful Drug Delivery Solutions
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This document contains forward - looking statements concerning TFF Pharmaceuticals, Inc . (“TFF”, the “Company,” “we,” “us,” and “our”) . The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate
Slide 3: Investment Highlights
3 Investment Highlights 3 Experienced Management; IP Protection Strong Internal Pipeline Broadly Applicable Platform Proprietary Lung Drug Delivery Process • Experienced senior management team with outstanding track record of success in a diverse set of competencies and related disciplines • Robust
Slide 4: Thin Film Freezing: Superior Drug Delivery to the Lung
4 Thin Film Freezing: Superior Drug Delivery to the Lung 4 The Problem Our Solution Oral Inhaled Typically , 10% of oral drugs reach their target and often contain bulking agents, fillers, and high dosages contributing to unwanted side effects. x Our TFF platform has shown the ability to deliver pre
Slide 5: Thin Film Freezing Process
5 Thin Film Freezing Process 5 Bulk drug material x Use proprietary combination of freezing rate and liquid surface to volume ratio x Confers advantages in engineering particles for various routes of administration x Stabilizes biologics not achievable with other process technologies Drying and lyop
Slide 6: TFF Platform Advantages
6 TFF Platform Advantages 6 Spray Drying Spray Freeze Drying Nano - Milling TFF Thermal Degradation ✘ x ✘ x Shear Stress ✘ ✘ ✘ x Air/Water Denaturation ✘ ✘ x x Technology Differentiators • Microparticles • Lower yield • Harder processing conditions • Microparticles • Lower yield • Variable particle
Slide 7: Delivering Value with an Internal Pipeline
7 Delivering Value with an Internal Pipeline 7 ASSET TFF VORI TFF TAC PLATFORM INDICATION Inhaled voriconazole (Antifungal) Invasive Pulmonary Aspergillosis (IPA) PRECLINICAL PHASE 1 PHASE 2 PHASE 3 • End of Phase 1 meeting with FDA • Initiated Phase 2 study • Positive compassionate use data (n=2) A
Slide 8: TFF VORI: Voriconazole Inhalation Powder for Invasive Pulmonary Aspergillosis
8 8 TFF VORI Voriconazole Inhalation Powder in Phase 2 for Invasive Pulmonary Aspergillosis
Slide 9: Market Opportunity: Invasive Pulmonary Aspergillosis (IPA)
9 9 Internal estimates and analyses * Maertens et al. Lancet 2016; 387:760 - 769. Market Opportunity: Invasive Pulmonary Aspergillosis (IPA) • Invasive pulmonary aspergillosis (IPA) is a respiratory mold infection caused by Aspergillus that primarily impacts immune compromised patients and is associ
Slide 10: The Problem: Toxicity due to IV and oral Voriconazole
10 10 • Voriconazole Package Insert; Warning and Precautions section, 5.2 and 5.3 Therapeutic window based on data from Pascual A et al. Clinical Infectious Diseases 2008. The Problem: Toxicity due to IV and oral Voriconazole Probability of toxicity 100% 50% 0.01 0.1 1 10 100 Voriconazole plasma con
Slide 11: TFF VORI Program (Inhaled Voriconazole)
11 11 TFF VORI Program (Inhaled Voriconazole) Targeted indication: Treatment of invasive pulmonary aspergillosis (IPA) and prophylaxis of IPA Preclinical POC data: • 3X better survival vs. amphotericin B in IPA Phase 1 data: • In healthy volunteers and patients with asthma, dosages up to 80mg twice
Slide 12: Preclinical Data of Inhaled Voriconazole
12 12 Preclinical Data of Inhaled Voriconazole Control Inhaled voriconazole Amphotericin B Control Inhaled voriconazole Amphotericin B *p<0.01 Increased survival Decreased necrotic lesions in the lung ~3x higher survival rate with inhaled VORI vs. AMB Tolman JA et al. Antimicrobial Agents and Chemot
Slide 13: Phase 1 Study Design
13 13 Phase 1 Study Design PART A: SINGLE ASCENDING DOSE 10 mg TFF VORI PART B: MULTIPLE ASCENDING DOSE N=32 healthy volunteers N=6 active + 2 placebo in each group N=32 healthy volunteers N=6 active + 2 placebo in each group BID dosing Design: • Randomized, double - blind, placebo - controlled stud
Slide 14: Phase 1 Results Showed TFF VORI was Safe and Well-Tolerated
14 14 Phase 1 Results Showed TFF VORI was Safe and Well - Tolerated x Most adverse events were grade 1 in severity and unrelated to TFF VORI x No clinically significant differences for vital signs, laboratory values, spirometry, visual exams, pulse oximetry, and ECGs x TFF VORI at up to the 80 mg le
Slide 15: Compassionate Use: Patient 1
15 15 Compassionate Use: Patient 1 Internal data and Oral Presentation: “Inhaled voriconazole: an effective novel antifungal delivery method which reduces syste mic absorption and toxicity.” Dr. Bradley Gardiner, Infectious Disease Physician, Royal Alfred Hospital. 9/8/22 • 50 - year - old man • Lun
Slide 16: Compassionate Use: Patient 2
16 16 Compassionate Use: Patient 2 Patient characteristics Internal Data • 54 - year - old woman • Lung transplant in 1993, treated with Tacrolimus • Multiple prior fungal infections • Prior treatment with systemic Voriconazole and Posaconazole • Posaconazole discontinued due to systemic toxicities
Slide 17: TFF VORI Phase 2 Study Design
17 TFF VORI Phase 2 Study Design Design: • A Phase 2, Open - Label, Randomized, Safety, Pharmacokinetic, and Efficacy Study of Voriconazole Inhalation Powder Compared to Oral Voriconazole Tablets in Subjects with Acute Invasive Pulmonary Aspergillosis (IPA) • n = 40 • Dosed at 80 mg inhaled or SOC d
Slide 18: TFF TAC: Tacrolimus Inhalation Powder for Lung Transplant Rejection
18 18 TFF TAC Tacrolimus Inhalation Powder in Phase 2 for Lung Transplant Rejection
Slide 19: Market Opportunity: Prophylaxis of Organ Rejection in Lung Transplants
19 19 Market Opportunity: Prophylaxis of Organ Rejection in Patients Receiving Lung Transplants • Lung transplantation is life - altering and life - saving, is limited by organ availability and rejection is a constant threat to graft and patient survival requiring lifelong immunosuppression Treatmen
Slide 20: The Problem: Toxicity due to Systemic Exposure of Tacrolimus
20 20 • Tacrolimus (PROGRAF®) Package Insert; Warning and Precautions section, 5.2 through 5.8; UNOS 2022 data The Problem: Toxicity due to Systemic Exposure of Tacrolimus Side effects: • Development of lymphoma and other malignancies, serious infections, polyoma virus infections, cytomegalovirus in
Slide 21: TFF TAC Program (Inhaled Tacrolimus)
21 21 TFF TAC Program (Inhaled Tacrolimus) Targeted Indication: • Prophylaxis of organ rejection in patients receiving lung transplants Preclinical POC Data: • Inhaled tacrolimus had similar efficacy compared to intramuscular tacrolimus in a rat lung transplant model Phase 1 data: • Successfully com
Slide 22: Preclinical Data of TFF TAC – Improved Drug Delivery to the Lung
22 22 Preclinical Data of TFF TAC – Improved Drug Delivery to the Lung Internal data Favorable lung distribution
Slide 23: Phase 1 Study Design
23 23 Phase 1 Study Design PART A: SINGLE ASCENDING DOSE PART B: MULTIPLE ASCENDING DOSE N=32 healthy volunteers N=6 active + 2 placebo in each group N=32 healthy volunteers N=6 active + 2 placebo in each group Design: • Randomized, double - blind, placebo - controlled study of TFF TAC in 64 healthy
Slide 24: Phase 1 Results Showed TFF TAC was Safe and Well-Tolerated
24 24 Phase 1 Results Showed TFF TAC was Safe and Well - Tolerated x Overall, TFF TAC was safe and well - tolerated x No dose - related increase in overall treatment - emergent adverse events (TEAEs) was observed Pharmacokinetics Safety https:// www.fda.gov /media/142632/download TFF TAC demonstrate
Slide 25: TFF TAC Phase 2 Study Design
25 TFF TAC Phase 2 Study Design Design: • Open label, multicenter, safety and PK study comparing safety, efficacy, and pharmacokinetic (PK) levels of TFF TAC in lung transplant patients that require reduced tacrolimus blood levels due to kidney toxicity • n = 24 • Part A: 12 - week safety, efficacy,
Slide 26: External Pipeline Leveraging TFF's Platform for Business Development Opportunities
26 26 External Pipeline Leveraging TFF’s Platform for Business Development Opportunities
Slide 27: Numerous Business Development Opportunities for TFF's Platform
27 Numerous Business Development Opportunities for TFF’s Platform Vaccines Reformulation and development of new vaccines eliminating need for cold chain supply requirements Ongoing discussions with multiple global pharma companies to test their proprietary compounds using the TFF technology platform
Slide 28: Disclosed Collaboration Partners
28 28 Disclosed Collaboration Partners Pharmaceutical and Biotechnology Partners Academic and Government Partners
Slide 29: TFF Leadership
29 29 TFF Leadership Chris Cano Chief Operating Officer & Vice President, Business Development • 20 years of corporate development experience • Previously served in senior business development roles at Aqua Pharmaceuticals, Duchesnay USA, Inc. and Noven Pharmaceuticals Harlan F. Weisman, M.D. Interi
Slide 30: TFF Board and Advisors
30 30 TFF Board and Advisors Aaron Fletcher, Ph.D. Chairman of the Board Robert S. Mills Director Stephen Rocamboli Director Board of Directors David N. Cornfield, M.D. Professor of Pulmonary Medicine, Stanford University Prof. David Denning, FRCP, FRCPath, DCH, FMedSci Professor of Infectious Disea
Slide 31: Key Takeaways
31 31 Key Takeaways Revolutionary platform enabling inhalable drug delivery across the entire spectrum of pharmaceutical agents (small & large molecules, biologics, vaccines, mRNA), targeting multiple $Billion - plus markets x Two proprietary, high commercial and lower risk clinical programs with si
Slide 32: Thank You
TFF PHARMACEUTICALS THANK YOU
TFF Pharmaceuticals — Investor Presentation (February 2023) on 6ix